Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 5 | 2023 | 600 | 0.520 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2023 | 251 | 0.500 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2023 | 174 | 0.440 |
Why?
|
| Radiosurgery | 3 | 2023 | 121 | 0.410 |
Why?
|
| Organs at Risk | 3 | 2023 | 70 | 0.340 |
Why?
|
| Radiation Oncology | 1 | 2023 | 23 | 0.220 |
Why?
|
| Brachytherapy | 1 | 2020 | 46 | 0.180 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2020 | 7 | 0.170 |
Why?
|
| SEER Program | 4 | 2020 | 93 | 0.170 |
Why?
|
| Urethral Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
| Neoplasms | 2 | 2022 | 1237 | 0.170 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2019 | 34 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 152 | 0.150 |
Why?
|
| Radiotherapy Dosage | 4 | 2023 | 247 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2023 | 444 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 224 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 394 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 402 | 0.130 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 83 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 325 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 282 | 0.120 |
Why?
|
| Models, Biological | 1 | 2017 | 723 | 0.110 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2011 | 33 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1189 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 60 | 0.090 |
Why?
|
| Humans | 12 | 2023 | 50389 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6223 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 915 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 750 | 0.070 |
Why?
|
| Middle Aged | 5 | 2020 | 12460 | 0.070 |
Why?
|
| Female | 6 | 2023 | 26981 | 0.060 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2018 | 28 | 0.060 |
Why?
|
| Aged | 4 | 2020 | 9590 | 0.060 |
Why?
|
| Lung | 2 | 2023 | 512 | 0.060 |
Why?
|
| Faculty | 1 | 2023 | 72 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 3180 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 227 | 0.050 |
Why?
|
| Adult | 4 | 2020 | 13568 | 0.050 |
Why?
|
| Male | 5 | 2020 | 25718 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 90 | 0.050 |
Why?
|
| Workplace | 1 | 2022 | 92 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 450 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 131 | 0.040 |
Why?
|
| United States | 2 | 2020 | 4913 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 418 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 466 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 142 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 671 | 0.040 |
Why?
|
| Uncertainty | 1 | 2018 | 43 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 641 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 2414 | 0.040 |
Why?
|
| Rural Population | 1 | 2022 | 552 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2018 | 235 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 1426 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1003 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5230 | 0.020 |
Why?
|
| Adolescent | 1 | 2011 | 6475 | 0.010 |
Why?
|